公开(公告)号：US20050101614A1

公开(公告)日：2005-05-12

申请号：US10916073

申请日：2004-08-11

申请人： Xao-Fa Lin ,  David Loughhead ,  Sanja Novakovic ,  Counde O'Yang ,  Michael Soth ,  David Putman

发明人： Xao-Fa Lin ,  David Loughhead ,  Sanja Novakovic ,  Counde O'Yang ,  Michael Soth ,  David Putman

IPC分类号： A61K31/416 ,  A61K31/4745 ,  A61K31/519 ,  A61P25/00 ,  C07D231/56 ,  C07D401/04 ,  C07D403/06 ,  C07D405/04 ,  C07D409/04 ,  C07D417/04 ,  C07D471/02 ,  C07D471/04 ,  C07D487/02 ,  C07D487/04

CPC分类号： C07D409/04 ,  C07D231/56 ,  C07D401/04 ,  C07D403/06 ,  C07D405/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

摘要： This invention relates to a method for modulating α2 subtype GABAA receptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain

摘要翻译： 本发明涉及用式I杂环化合物调节α2亚型GABA A A受体的方法及其盐，溶剂合物和前药。 本发明还涉及含有所述化合物的新型杂环化合物和药物组合物。 此外，本发明涉及抑郁症，焦虑障碍，精神障碍，学习或认知障碍，睡眠障碍，惊厥或发作性疾病或疼痛的治疗

公开(公告)号：US20050197330A1

公开(公告)日：2005-09-08

申请号：US11061000

申请日：2005-02-18

申请人： David Loughhead ,  Sanja Novakovic ,  Counde O'Yang ,  David Putman ,  Michael Soth

发明人： David Loughhead ,  Sanja Novakovic ,  Counde O'Yang ,  David Putman ,  Michael Soth

IPC分类号： A61K31/437 ,  A61K31/498 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/542 ,  C07D471/04 ,  C07D487/02 ,  C07D487/04 ,  C07D491/02 ,  C07D498/02 ,  C07D498/04 ,  C07D513/04

CPC分类号： A61K31/437 ,  A61K31/5383 ,  C07D471/04 ,  C07D487/04

摘要： This invention relates to a method for modulating α2 subtype GABAA receptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain

摘要翻译： 本发明涉及用式I杂环化合物调节α2亚型GABA A A受体的方法及其盐，溶剂合物和前药。 本发明还涉及含有所述化合物的新颖的杂环化合物和药物组合物。 此外，本发明涉及抑郁症，焦虑障碍，精神障碍，学习或认知障碍，睡眠障碍，惊厥或发作性疾病或疼痛的治疗

公开(公告)号：US20060135555A1

公开(公告)日：2006-06-22

申请号：US11348036

申请日：2006-02-06

申请人： David Loughhead ,  Counde O'Yang

发明人： David Loughhead ,  Counde O'Yang

IPC分类号： A61K31/4745 ,  C07D471/02

CPC分类号： C07D471/04 ,  C07D487/04

摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R1-R4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

公开(公告)号：US20070213373A1

公开(公告)日：2007-09-13

申请号：US11799605

申请日：2007-05-02

申请人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

发明人： Richard Cournoyer ,  David Loughhead ,  Counde O'Yang

IPC分类号： A61K31/416 ,  A61K31/4439

CPC分类号： C07D209/44 ,  C07D231/56 ,  C07D401/04

摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

摘要翻译： 本发明涉及通常为CRF-1受体拮抗剂并由式I或式II表示的化合物：其中R 3是任选取代的芳基或杂芳基，R 1， 和R 2如本说明书中所定义; 或各异构体，异构体的外消旋或非外消旋混合物或其药学上可接受的盐。 本发明还涉及制备这些化合物的方法，含有这些化合物的药物组合物及其用作治疗剂的方法。

公开(公告)号：US20050014781A1

公开(公告)日：2005-01-20

申请号：US10914368

申请日：2004-08-09

申请人： David Loughhead ,  Coude O'Yang

发明人： David Loughhead ,  Coude O'Yang

IPC分类号： A61K31/437 ,  A61K31/438 ,  A61K31/444 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/55 ,  A61P1/04 ,  A61P1/06 ,  A61P1/14 ,  A61P3/04 ,  A61P5/00 ,  A61P5/04 ,  A61P7/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P15/00 ,  A61P15/06 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P25/36 ,  A61P29/00 ,  A61P31/00 ,  A61P31/18 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08 ,  A61P41/00 ,  A61P43/00 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D471/02 ,  A61K31/4745

CPC分类号： C07D471/04 ,  C07D487/04

摘要： This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R1-R4 are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

摘要翻译： 本发明涉及通常为CRF-1受体拮抗剂并由式I或式II表示的化合物：其中Ar为任选取代的芳基或杂芳基，R 1 -R 4如说明书中所定义; 或各异构体，异构体的外消旋或非外消旋混合物或其药学上可接受的盐。 本发明还涉及制备这些化合物的方法，含有这些化合物的药物组合物及其用作治疗剂的方法。